Surrozen, Inc. has announced its financial results for the third quarter of 2026, a crucial update for stakeholders and investors in the biological products sector. The report, filed with the SEC on November 9, 2026, provides insights into the company's operational performance and financial health.

Background

Surrozen, Inc. is a Delaware-based company operating in the biological products industry, specifically categorized under SIC code 2836, which pertains to biological products (no diagnostic substances). The company trades on the Nasdaq under the ticker symbol SRZN. Surrozen has been active in the market, with several recent filings, including a 10-Q report and multiple Schedule 13 filings.

What the Filing Says

In the filing, Surrozen disclosed that it issued a press release detailing its financial results for the quarter ended September 30, 2026. The filing states, "On November 9, 2026, Surrozen, Inc. (the 'Company') issued a press release announcing its financial results for the quarter ended September 30, 2026." A copy of the press release is attached as Exhibit 99.1 to the report.

Impact

The financial results may affect various stakeholders, including investors, analysts, and potential partners. Investors will be particularly interested in the company's revenue growth, profit margins, and strategic direction. Additionally, competitors in the biological products sector will likely analyze Surrozen's performance to gauge their market position and adjust their strategies accordingly.

What's Next

The filing does not say what happens next. However, the financial results may lead to further discussions among investors and analysts regarding the company's future strategies and potential growth opportunities.